4//SEC Filing
INNOVUS PHARMACEUTICALS, INC. 4
Accession 0001144204-14-010903
CIK 0001411879operating
Filed
Feb 20, 7:00 PM ET
Accepted
Feb 21, 6:04 AM ET
Size
7.3 KB
Accession
0001144204-14-010903
Insider Transaction Report
Form 4
Damaj Bassam
DirectorPresident and CEO10% Owner
Transactions
- Conversion
Common Stock
2014-02-19+1,190,411→ 1,708,265 total
Holdings
- 129,393(indirect: By Spouse)
Common Stock
- 6,852,272
Restricted Stock Unit
→ Common Stock (852,272 underlying)
Footnotes (3)
- [F1]Conversion of January 15, 2103 Line of Credit 8% Debenture at $0.40 per share.
- [F2]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F3]Issued as a year end bonus pursuant to Reporting Person's employment agreement. The Reporting Person was granted a fully vested Restricted Stock Unit awarded on February 6, 2014. The Restricted Stocks Units will settle upon the earliest to occur of (1) the Reporting Person's service termination date, (ii) a change in control or (iii) February 6, 2021
Documents
Issuer
INNOVUS PHARMACEUTICALS, INC.
CIK 0001411879
Entity typeoperating
IncorporatedNV
Related Parties
1- filerCIK 0001411879
Filing Metadata
- Form type
- 4
- Filed
- Feb 20, 7:00 PM ET
- Accepted
- Feb 21, 6:04 AM ET
- Size
- 7.3 KB